Seeking Alpha

James Stocklasar Thomas Jr.

 
View as an RSS Feed
View James Stocklasar Thomas Jr.'s Articles BY TICKER:
  • Savvy Investors Discover Antares' Growing Revenue Stream
    Jan. 17, 2013 ATRS 15 Comments
  • The Future Of Zalicus In 2013
    Jan. 15, 2013 EPRS 39 Comments
  • Recalculating Celsion's Upcoming Results
    Jan. 14, 2013 CLSN 33 Comments
  • Why Is Antares Rising So Quickly?
    Jan. 9, 2013 ATRS 34 Comments
  • Why Growth Stock Antares Is Moving Higher
    Jan. 7, 2013 ATRS 29 Comments
  • Celsion: The Heat Is On
    Jan. 2, 2013 CLSN 21 Comments
  • Sizing Up Celsion's Odds Of Success
    Dec. 21, 2012 CLSN 22 Comments
  • Why Celsion Is A Strong Buy On The Dip
    Dec. 17, 2012 CLSN 23 Comments
  • Pre-HEAT Celsion Catalysts Confirm Strong Buy
    Dec. 14, 2012 CLSN 9 Comments
  • A Reasoned Case For Celsion's ThermoDox
    Dec. 10, 2012 CLSN 20 Comments
  • Cel-Sci: Immunotherapy Opens New Door To Investors
    Dec. 6, 2012 CVM 18 Comments
  • Buying Teva's Immunotherapy Investment
    Dec. 5, 2012 TEVA 9 Comments
  • Top 5 Fiscal Cliff Biotech Buys
    Dec. 5, 2012 AMRN, ARNA, CLSN 10 Comments
  • Smart Day Traders Ring The Register On Acadia And Zalicus
    Nov. 28, 2012 ACAD, CPRX, SNY 15 Comments
  • Why Cash Overrules The Momentary Market Bounce
    Nov. 27, 2012 ACAD, AEZS, ARNA 14 Comments
  • Why I'm 'In Cash' For Biotechs In A Bearish Market
    Nov. 21, 2012 AEZS, ARNA, ASTX 37 Comments
  • Acadia's Bubbling To Move Higher
    Oct. 18, 2012 ACAD 24 Comments
  • Why Acadia May Be This Year's Holiday Prize
    Oct. 17, 2012 ACAD 28 Comments
  • Time To Buy Housing Stocks Like DR Horton
    Oct. 15, 2012 DHI 1 Comment
  • How Sirius Could Grow Its Bottom Line
    Oct. 15, 2012 SIRI 33 Comments
  • BioClinica: A Stealth Stock For Savvy Buyers?
    Oct. 3, 2012 BIOC Comment!
  • Reconsidering Zalicus And Antares In Light Of Shakeups
    Oct. 3, 2012 ATRS, ACAD, NVS 18 Comments
  • A Reasoned Case For Pimavanserin's Success
    Sep. 24, 2012 ACAD 10 Comments
  • Under Construction Rehash: Buy Acadia And Astex
    Sep. 20, 2012 ACAD, AEZS, ASTX 24 Comments
  • More Evidence For Catalyst's Potential Vigabatrin Success
    Editors' Pick • Sep. 17, 2012 CPRX 23 Comments
  • Buying Into Catalyst Pharma's Fast Tracked Vigabatrim On Friday
    Sep. 14, 2012 CPRX 36 Comments
  • Zalicus Misses Key Secondary Endpoint
    Sep. 10, 2012 EPRS 30 Comments
  • Astex's Linear Rise Versus Peregrine's And Cell Therapeutics' Sudden Pop
    Sep. 10, 2012 ASTX 15 Comments
  • Bulls Keep Knocking On Astex's Door
    Sep. 4, 2012 ASTX 12 Comments
  • Zalicus: When Push Comes To Shove
    Aug. 31, 2012 EPRS 77 Comments
  • Early Thursday: Make Money On Zalicus, Why Not?
    Aug. 30, 2012 EPRS 22 Comments
  • Going Into Monday Zalicus' S-3 Surprise
    Aug. 27, 2012 EPRS 30 Comments